These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7752260)

  • 1. Re: Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells.
    Pollak M
    J Natl Cancer Inst; 1995 Apr; 87(8):608-9. PubMed ID: 7752260
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells.
    Donat SM; Powell CT; Israeli RS; Fair WR; Heston WD
    J Natl Cancer Inst; 1995 Jan; 87(1):41-6. PubMed ID: 7666462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors.
    Peehl DM; Wong ST; Stamey TA
    J Urol; 1991 Mar; 145(3):624-30. PubMed ID: 1705296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
    J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective stimulation of prostatic carcinoma cell proliferation by transferrin.
    Rossi MC; Zetter BR
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6197-201. PubMed ID: 1631108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The enhancement of the chemotherapeutic effects on human prostate cancer cell--the combination with the growth factor interaction inhibitor (suramin)].
    Suzuki Y; Miwa Y; Akino H; Fujita T; Saikawa S; Kanimoto Y; Okada K
    Hinyokika Kiyo; 1993 Dec; 39(12):1215-20. PubMed ID: 8285172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer.
    Eisenberger MA; Fontana JA
    J Natl Cancer Inst; 1992 Jan; 84(1):3-5. PubMed ID: 1738171
    [No Abstract]   [Full Text] [Related]  

  • 8. [Potentiation of cytotoxicity of electromagnetic shock waves by suramin, "in vitro" study].
    Rosell D; Robles JE; Aguera L; Abad JI; Rodríguez-Rubio FI; Zudaire JJ; Berian JM
    Actas Urol Esp; 1994 Jan; 18(1):29-33; discussion 34. PubMed ID: 8191943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
    Samid D; Shack S; Myers CE
    J Clin Invest; 1993 May; 91(5):2288-95. PubMed ID: 8486788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of suramin alone or in combination with DHT and PDGF on the cell proliferation of benign and malignant human prostatic tissues in organ cultures.
    Michel P; Van Velthoven R; Petein M; Gras S; Etievant C; Pasteels JL; Kiss R
    Anticancer Res; 1991; 11(6):2075-8. PubMed ID: 1723262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
    Myers C; Cooper M; Stein C; LaRocca R; Walther MM; Weiss G; Choyke P; Dawson N; Steinberg S; Uhrich MM
    J Clin Oncol; 1992 Jun; 10(6):881-9. PubMed ID: 1375283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
    Arah IN; Dixon SC; Horti J; Figg WD
    Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin.
    Palayoor ST; Bump EA; Teicher BA; Coleman CN
    Radiat Res; 1997 Aug; 148(2):105-14. PubMed ID: 9254728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered response to thyroid hormones by prostate and breast cancer cells.
    Martinez MB; Ruan M; Fitzpatrick LA
    Cancer Chemother Pharmacol; 2000; 45(2):93-102. PubMed ID: 10663623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism.
    Rago R; Mitchen J; Cheng AL; Oberley T; Wilding G
    Cancer Res; 1991 Dec; 51(24):6629-35. PubMed ID: 1742736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines.
    Fruehauf JP; Myers CE; Sinha BK
    J Natl Cancer Inst; 1990 Jul; 82(14):1206-9. PubMed ID: 2362291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin reverses the anti-invasive activity of human prostate cancer cells that overexpress sema3E.
    Herman JG; Meadows GG
    Int J Oncol; 2007 Nov; 31(5):1267-72. PubMed ID: 17912456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of fibroblast hyaluronic acid production by suramin.
    August EM; Duncan KL; Malinowski NM; Cysyk RL
    Oncol Res; 1993; 5(10-11):415-22. PubMed ID: 8054702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UK studies on suramin therapy in hormone resistant prostate cancer.
    Kehinde EO; Terry TR; Mistry N; Horsburgh T; Sandhu DP; Bell PR
    Cancer Surv; 1995; 23():217-29. PubMed ID: 7621460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
    LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
    Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.